



ASX ANNOUNCEMENT

22 May 2017

ESENSE-LAB RESEARCH AND DEVELOPMENT UPDATE

Life sciences company **eSense-Lab Ltd** (“**eSense**” or the “**Company**”), (**ASX: ESE**), is pleased to update its shareholders on the Company’s research and development (R&D) activities.

As outlined in its IPO prospectus, eSense has unique analytical capabilities and intellectual property surrounding the phytochemical profiling of plants; combining genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants.

Having successfully entered the medical cannabis plant vertical, and alongside the recent announcement of commercial sales within this sector, the Company will now expand its R&D focus towards other plants, with a particular interest in those which are rare, have high extract value, impose large environmental footprints and undergo traditional extraction methods which are compound degrading in their process.

The Company has identified potential market opportunities and will be particularly focused on Sandalwood, Ginseng and Saffron, amongst others.

Commenting on the announcement, CEO Haim Cohen, said: “Having successfully penetrated our first plant vertical in the medical cannabis space and delivering our first revenues, we are well positioned to explore other rare plants which are of commercial potential to us. Having announced a number of key scientific and technological advancements in the recent months, our team is very excited to explore broader opportunities. This R&D is complementary to our existing operations, and will not take away from our current focus to continue to rapidly expand our existing commercial opportunities in our current vertical, being the medical cannabis and its complementary sectors.”

eSense will continue to update its shareholders on further developments.

Ends

About eSense-Lab

eSense-Lab (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to ‘reverse engineer’ a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant’s health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost.

To learn more about eSense – Lab, visit www.esense-lab.com

**Investor Relations****FTI Consulting**

Level 2, 2 Kings Park Rd

West Perth WA 6005

+61 (0)8 9485 8888

Elodie.Castagna@fticonsulting.com

Steve.Suleski@fticonsulting.com

www.fticonsulting.com

Corporate Advisors**Otsana Capital**

108 Outram Street

West Perth WA 6005

Telephone: +61 8 9486 7244

www.otsana.com